Citations

Clear

3042 citation(s) found for "Kumar, S".

The Renal–Cardiac Connection in Subjects with Preserved Ejection Fraction: A Population Based Study
Jain, Amit Kumar C , Chen, Horng H. , Scott, Christopher G.

Mayo Clinic

ESC Heart Failure | May 17, 2017 | Volume: 4 | Issue: 3 | Pages: 266-273

10.1002/ehf2.12143 | PMID 28772030 Get It

Abstract Aims Chronic kidney disease (CKD) is prevalent and is associated with increased cardiovascular morbidity and mortality. The interaction between diastolic dysfunction (DD) and CKD in subjects with preserved systolic function is not well defined. This study sought to determine the association between renal function and DD in subjects with preserved ejection fraction. Methods and results Through the Rochester Epidemiology Project, subjects who underwent echocardiography over 2 years with EF ≥50% were identified and the clinical data were obtained. Glomerular filtration rate (GFR) was estimated using the modification of diet in renal disease equation. Linear regression was used to test for association of GFR and DD. DD was defined as follows: Grade 2 or pseudonormal pattern (0.75 < E/A ≤ 1.5, E/e′ ≥ 10, DT > 140 ms, ΔE/A ≥ 0.5, and PV S < D) or Grade 3+ or restrictive pattern (E/A > 1.5, E/e′ ≥ 10, DT < 140 ms, and PV S < D). Cox regression was used to assess correlation of GFR and DD with time-to-event outcomes. A total of 2056 patients were identified. There was significant correlation between worsening GFR and degree of DD assessed by echo Doppler E/e′ ratio (P = 0.005), left ventricular mass index (P = 0.004), and right ventricular systolic pressure (P = 0.01). Worsening GFR was associated with increased mortality, development of heart failure, and hospitalization (P < 0.001). Within each GFR group, abnormal DD was associated with a higher risk of the clinical outcomes. No interaction between GFR and DD was noted, suggesting an increased risk of events associated with abnormal DD across ranges of GFR. Conclusions Worsening GFR was associated with a greater degree of diastolic dysfunction and adverse clinical outcomes. Within each GFR group, the presence of DD was associated with increased morbidity and mortality. Further studies are warranted to determine if improving DD in patients with CKD will benefit clinical outcomes.
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Kumar, Shaji , Moreau, Philippe , Mateos, María‐Victoria , Shustik, Chaim, Masszi, Tamás , Spencer, Andrew , Hájek, Roman , Romeril, Kenneth, Avivi, Irit , Liberati, Anna Marina , Berg, Deborah, Lin, Jianchang , Gupta, Neeraj , Esseltine, Dixie‐Lee, Richardson, Paul G. , Einsele, Hermann , Gupta, Neeraj , Hari, Parameswaran , Ludwig, Heinz , Minnema, Monique C , Lonial, Sagar , Richardson, Paul Gerard Guy , Hajek, Roman , Moreau, Philippe , Masszi, Tamas

Mayo Clinic

British Journal of Haematology | May 9, 2017 | Volume: 178 | Issue: 4 | Pages: 571-582

10.1111/bjh.14733 | PMID 28485007 Get It

SummaryThe oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was based on the global, randomised, double‐blind, placebo‐controlled Phase III TOURMALINE‐MM1 study of ixazomib‐Rd (IRd) versus placebo‐Rd in patients with relapsed/refractory multiple myeloma. IRd resulted in a significant improvement in progression‐free survival versus placebo‐Rd (median: 20·6 vs. 14·7 months; hazard ratio 0·74). Common toxicities observed more commonly with IRd versus placebo‐Rd were thrombocytopenia, nausea, vomiting, diarrhoea, constipation, rash, peripheral neuropathy, peripheral oedema and back pain; these were generally grade 1/2 in severity except for thrombocytopenia (19% vs. 9% grade 3/4), which appeared manageable and reversible, with no differences between arms in significant bleeding or dose discontinuations. No cumulative toxicities were observed, indicating the potential feasibility of long‐term IRd treatment. Safety data from TOURMALINE‐MM1 are reviewed and guidance for managing clinically relevant adverse events associated with IRd is provided. Most toxicities were manageable with supportive care and dose delays or reductions as needed. Clinicians should be aware of and understand these potential side effects to optimise and prolong patient benefit.
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis
Muchtar, Eli , Dean, Diana S., Dingli, David , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Russell, Stephen J. , Lust, John A., Lin, Yi , Warsame, Rahma , Kourelis, Taxiarchis , Chakraborty, Rajshekhar , Zeldenrust, Steven R., Kyle, Robert A. , Kumar, Shaji , Muchtar, E , Dispenzieri, Angela , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Go, Ronald S. , Rajkumar, S. Vincent , Gertz, Morie A. , Russell, Stephen J , Chakraborty, Rajshekhar , Dingli, David , Lin, Yi

Mayo Clinic

Journal of Internal Medicine | April 25, 2017 | Volume: 281 | Issue: 6 | Pages: 611-619

10.1111/joim.12617 | PMID 28439924 Get It

AbstractBackgroundData on the effect of systemic immunoglobulin light chain amyloidosis (AL amyloidosis) on thyroid function are limited.ObjectiveTo assess the prevalence of hypothyroidism in AL amyloidosis patients and determine its predictors.Methods1142 newly diagnosed AL amyloidosis patients were grouped based on the thyroid‐stimulating hormone (TSH) measurement at diagnosis: hypothyroid group (TSH above upper normal reference; >5 mIU L−1; n = 217, 19% of study participants) and euthyroid group (n = 925, 81%). Predictors for hypothyroidism were assessed in a binary multivariate model. Survival between groups was compared using the log‐rank test and a multivariate analysis.ResultsPatients with hypothyroidism were older, more likely to present with renal and hepatic involvement and had a higher light chain burden compared to patients in the euthyroid group. Higher proteinuria in patients with renal involvement and lower albumin in patients with hepatic involvement were associated with hypothyroidism. In a binary logistic regression model, age ≥65 years, female sex, renal involvement, hepatic involvement, kappa light chain restriction and amiodarone use were independently associated with hypothyroidism. Ninety‐three per cent of patients in the hypothyroid group with free thyroxine measurement had normal values, consistent with subclinical hypothyroidism. Patients in the hypothyroid group had a shorter survival compared to patients in the euthyroid group (4‐year survival 36% vs 43%; P = 0.008), a difference that was maintained in a multivariate analysis.ConclusionA significant proportion of patients with AL amyloidosis present with hypothyroidism, predominantly subclinical, which carries a survival disadvantage. Routine assessment of TSH in these patients is warranted.
Development of Distinct Body Mass Index Trajectories Among Children Before Age 5 Years: A Population-Based Study
Lynch, Brian , Ebbert, Jon O. , Kumar, Seema , Yawn, Barbara P. , Jacobson, Debra J., Sauver, Jennifer L. St. , Lynch, Brian A, Jacobson, Debra, Rutten, Lila J. Finney , St Sauver, Jennifer L

Mayo Clinic

Journal of Primary Care & Community Health | April 22, 2017 | Volume: 8 | Issue: 4 | Pages: 278-284

10.1177/2150131917704326 | PMID 28434273 Get It

The prevalence of childhood obesity has increased over the past 3 decades. This study was designed to understand how childhood body mass index (BMI) influences later risk of obesity. We calculated BMIs for children residing in Olmsted County, Minnesota, between January 1, 2005 and December 31, 2012 using medical records data. We defined homogenous BMI trajectory clusters using a nonparametric hill-climbing algorithm. Overall, 16,538 (47%) children had >3 weight assessments at least 1 year apart and were included in the analyses. Within the 8-year follow-up period, children who were younger than 2 years and overweight had a 3- fold increase of obesity (adjusted hazard ratio [HR] = 3.24; 95% confidence interval [CI] = 2.69-3.89) and those aged 5 years and overweight had a 10-fold increased risk of obesity (adjusted HR = 9.97, 95% CI = 8.55-11.62). Three distinct BMI trajectories could be distinguished prior to 5 years of age. The risk of developing obesity in those who are overweight increased dramatically with increasing age. Interventions to prevent obesity need to occur prior to school age to prevent children from entering unhealthy BMI trajectories.
Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis
Abeykoon, Jithma P. , Dingli, David , Baudi, Francis K., Kyle, Robert A. , Lacy, Martha Q. , Hayman, Suzanne R. , Kourelis, Taxiarchis , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Dispenzieri, Angela , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Rajkumar, S. Vincent , Dingli, David

Mayo Clinic

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 50-51

10.1080/13506129.2017.1286584 | PMID 28434368 Get It

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Auclair, Daniel , Kelloff, Gary J. , Sigman, Caroline C. , Avet‐Loiseau, Hervé , Farrell, Ann T. , Gormley, Nicole , Kumar, Shaji , Munshi, Nikhil C. , Cavo, Michèle , Davies, Faith E. , Bacco, Alessandra Di , Dickey, Jennifer S., Gutman, Steven, Higley, Howard R., Hussein, Mohamad A., Jessup, J. Milburn , Little, Richard F. , Loberg, Robert D., Lohr, Jens G. , Mukundan, Lata , Omel, James, Pugh, Trevor J. , Reaman, Gregory H. , Robbins, Michael , Sasser, A. Kate, Valente, Nancy, Zamagni, Elena , Anderson, Kenneth C. , Landgren, Ola , Kirsch, Ilan R. , Pugh, Trevor J , Davies, Faith E , Gormley, Nicole , Zamagni, Elena

Mayo Clinic

Clinical Cancer Research | April 20, 2017 | Volume: 23 | Issue: 15 | Pages: 3980-3993

10.1158/1078-0432.ccr-16-2895 | PMID 28428191 Get It

Abstract Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new sensitive and specific tools for disease prognostication and management. Assessment of minimal residual disease (MRD) in response to therapy is one of these tools, as longer progression-free survival (PFS) is seen consistently among patients who have achieved MRD negativity. Current therapies lead to unprecedented frequency and depth of response, and next-generation flow and sequencing methods to measure MRD in bone marrow are in use and being developed with sensitivities in the range of 10−5 to 10−6 cells. These technologies may be combined with functional imaging to detect MRD outside of bone marrow. Moreover, immune profiling methods are being developed to better understand the immune environment in myeloma and response to immunomodulatory agents while methods for molecular profiling of myeloma cells and circulating DNA in blood are also emerging. With the continued development and standardization of these methodologies, MRD has high potential for use in gaining new drug approvals in myeloma. The FDA has outlined two pathways by which MRD could be qualified as a surrogate endpoint for clinical studies directed at obtaining accelerated approval for new myeloma drugs. Most importantly, better understanding of MRD should also contribute to better treatment monitoring. Potentially, MRD status could be used as a prognostic factor for making treatment decisions and for informing timing of therapeutic interventions. Clin Cancer Res; 23(15); 3980–93. ©2017 AACR.
Nano‐curcumin safely prevents streptozotocin‐induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus
Ganugula, Raghu , Jaisamut, Patcharawalai , Wiwattanapatapee, Ruedeekorn , Venkatpurwar, Vinod, Hoffmann, Aline Rodrigues , Basu, Rita , Kumar, M. N. V. Ravi , Majeti, Naga Venkata Ravi Kumar , Arora, Meenakshi , Jørgensen, Heather G. , Zhou, Beiyan , Guo, Shaodong

Mayo Clinic

British Journal of Pharmacology | April 13, 2017 | Volume: 174 | Issue: 13 | Pages: 2074-2084

10.1111/bph.13816 | PMID 28409821 Get It

Background and PurposeApproaches to prevent selective and progressive loss of insulin‐producing beta cells in Type 1 diabetes mellitus (T1DM) will help to manage this prevalent and devastating disease. Curcumin (CUR), a natural anti‐inflammatory substance, suppresses diabetes‐associated inflammation and cell death. However, very high doses need to be used because of poor oral bioavailability, making it difficult to translate the anti‐inflammatory actions to clinical situations.Experimental ApproachWe have prepared biodegradable nanosystems encapsulating curcumin (nCUR), resulting in at least nine‐fold improvement in oral bioavailability. Here, we tested the ability of nCUR to prevent streptozotocin (STZ)‐induced inflammation and apoptosis in pancreatic islets and beta cells, in rats.Key ResultsNon‐fasted rats pretreated with 10 or 50 mg·kg−1 nCUR 6 h prior to STZ challenge had up to 37% reduction in the glucose levels, while plain CUR (50 mg·kg−1) results in 12% reduction. This treatment with nCUR was accompanied by decreased islet or beta cell death, as shown by TUNEL assay and H&E staining. Both CUR and nCUR significantly decreased levels of inflammatory cytokines in pancreatic tissue homogenates that correlated well with minimal histiocytic infiltration. Pre‐treatment with nCUR, but not CUR, decreased 8‐oxo‐2′‐deoxyguanosine, a sensitive biomarker of ROS‐induced DNA damage, in pancreas. In normal rodents, daily dosing for 28 days, with nCUR (25‐100 mg·kg−1) did not cause any deleterious health issues by the carrier.Conclusions and ImplicationsTogether, these data indicate a potentially translatable dose of nCUR that is safe and efficacious in improving beta cell function, which could prevent T1DM.
Differential Accumulation of Secreted AβPP Metabolites in Ocular Fluids1
Prakasam, A. , Muthuswamy, Anusuya, Ablonczy, Zsolt, Fauq, Abdul H. , Rao, K. S. , Pappolla, Miguel A. , Sambamurti, Kumar , Fauq, Abdul, Greig, Nigel H.

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 20 | Issue: 4 | Pages: 1243-1253

10.3233/jad-2010-100210 | PMID 20413851 Get It

Amyloid-β (Aβ) accumulates in several types of retinal degeneration and in Alzheimer’s disease (AD), but its source has been unclear. We detected the neuronal 695 amino acid form of amyloid-β protein precursor (AβPP) in the normal retina and AβPP751 in the retinal pigment epithelium (RPE) and anterior eye tissues. Similar to the brain, a- and β-secretases cleaved AβPP to soluble derivatives (sAβPP) a or β and membrane-bound C-terminal fragments a or β in the retina and RPE. Levels of sAβPP were particularly high in the vitreous and low in aqueous humor revealing a molecular barrier for AβPP. In contrast, Aβ40 and Aβ42 levels were only 50% lower in the aqueous than the vitreous humor, indicating relatively barrier-free movement of Aβ. These studies demonstrated a relatively high yield of AβPP and Aβ in the ocular fluids, which may serve as a trackable marker for AD. In addition, failure of free clearance from the eye may trigger retina degeneration in a manner similar to Aβ-related neurodegeneration in AD.